Lung cancer IHC portfolio
Deliver diagnostic confidence with the lung IHC portfolio
The statistics associated with lung cancer clearly demonstrate the aggressive nature of this deadly disease. Roche Diagnostics offers a robust menu of lung cancer diagnostic tools.
VENTANA prediluted, optimized reagents
Our antibodies are ready-to-use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. VENTANA prediluted, optimized reagents consistently demonstrate superior performance when compared with concentrated antibodies that require manual dilution and in-house validation.
Proven portfolio of lung cancer assays
Our proven portfolio of lung cancer assays can assist in the stratification of disease, including non-small cell lung carcinoma (NSCLC), neuroendocrine carcinoma and their various subtypes.
p40 (BC28) Mouse Monoclonal Primary Antibody1
- Found to be as or more sensitive than p632,3,4
- Studies indicate p40 has higher specificity in squamous cell carcinoma than p632,3,4
- May offer a suitable replacement for p63 in various tumor types5,6
- Can be used in a stratification panel with other key markers7,8
TTF-1 (SP141) Rabbit Monoclonal Primary Antibody
- Aids in investigation of metastatic carcinomas of unknown origin9
- Equal or better lung carcinoid detection than other on-market clones10
- Commonly used in lung stratification panels with other key markers7,8
Cytokeratin 5/6 (D5/16B4) Mouse Monoclonal Primary Antibody
- Aids in the identification of squamous cell carcinoma11
- Aids in the differentiation of malignant mesothelioma from lung adenocarcinoma12
- Commonly used in a stratification panel with other markers7,8
Napsin A (MRQ-60) Mouse Monoclonal Primary Antibody
- Useful in the identification of primary and metastatic carcinomas of the lung13
- Highly specific for lung adenocarcinoma7
- Commonly used in a lung stratification panel with other key markers7,8
